AI Terminal
Assura PLC
Regulatory Filings • May 21, 2024
4924_rns_2024-05-21_2edb5ac3-b76a-4363-a43f-50b7685456df.html
Regulatory Filings
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 1876P
Assura PLC
21 May 2024
21 May 2024
Assura plc
Appointment of Joint Corporate Broker
Assura plc is pleased to announce that it has appointed HSBC Bank plc to act as its joint corporate broker alongside Barclays Bank plc and Stifel Nicolaus Europe Ltd, with immediate effect.
- Ends -
For more information, please contact:
| Assura plc David Purcell, Investor Relations Director |
Tel: 0161 515 2043 E mail: [email protected] |
| Finsbury Glover Hering Gordon Simpson HSBC Bank plc Chloe Ponsonby / Sam McLennan Barclays Bank plc Bronson Albery / Tom MacDonald Stifel Nicolaus Europe Ltd Mark Young / Jonathan Wilkes-Green |
Tel: 0207 251 3801 Email: [email protected] Tel: +44 (0) 20 7991 8888 Tel: +44 (0) 207 623 2323 Tel: +44 (0) 20 7710 7600 |
Notes to Editors
Assura plc is the UK's leading specialist healthcare property investor and developer. Assura enables better health outcomes through its portfolio of more than 600 healthcare buildings, from which over six million patients are served.
A UK REIT based in Altrincham, Assura is a constituent of the FTSE 250 and the EPRA* indices. As at 31 March 2024, Assura's portfolio was valued at £2.7 billion and has a strong track record of growing financial returns and dividends for shareholders.
At Assura, we BUILD for health, having developed over 100 new healthcare buildings in our history, and at the heart of our strategy sits The Bigger Picture; Healthy Environment (E), Healthy Communities (S), Healthy Business (G).
Further information is available at www.assuraplc.com
* EPRA is a registered trademark of the European Public Real Estate Association
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
APPDZGZKGGVGDZZ